GLP1R and inflammatory bowel disease: Furthermore, by addressing metabolic dysfunction in obese patients, whose prevalence is increasing in the IBD population (13), GLP-1 RAs could indirectly mitigate inflammation by decreasing the pro-inflammatory activity of adipose tissue, particularly visceral adipose one.